RG
RGEN
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Stanley Druckenmiller | Duquesne Family Office | $11M | 0.2% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $0M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Repligen Corp. (RGEN) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for RGEN — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 47.10 | NEUTRAL |
| Stochastic %K (14) | 14.63 | BUY |
| CCI (20) | -113.67 | BUY |
| Williams %R (14) | -85.37 | BUY |
| MACD (12,26,9) | -2.73 | SELL |
| ROC (10) | -8.66 | SELL |
| Momentum (10) | -15.62 | SELL |
| EMA (10) | 169.83 | SELL |
| SMA (10) | 171.77 | SELL |
| EMA (20) | 169.21 | SELL |
| SMA (20) | 173.43 | SELL |
| EMA (30) | 165.96 | SELL |
| SMA (30) | 167.52 | SELL |
| EMA (50) | 159.10 | BUY |
| SMA (50) | 157.19 | BUY |
| EMA (100) | 148.91 | BUY |
| SMA (100) | 140.05 | BUY |
| EMA (200) | 146.70 | BUY |
| SMA (200) | 142.15 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Repligen Corp.
Healthcare · Medical Instruments & Supplies
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-07-22
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
No real edge — avoid
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.